Coya Therapeutics study shows immune dysfunction in dementia patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq set for best quarter since 2020 despite Iran warÂ
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring
March 18, 2026 8:00 AM EDTStudy results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD
Low-dose IL-2 plus CTLA-4 Ig has previously demonstrated restoration of regulatory T-cell function together with reduction of inflammatory cytokines and monocyte activation in treated patients
Findings of this biomarker... More
